Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Buserelin acetate
Drug ID BADD_D00315
Description Buserelin is a synthetic peptide analog of the luteinizing hormone-releasing hormone (LHRH) agonist, which stimulates the pituitary gland's gonadotrophin-releasing hormone receptor (GnRHR). It is used in prostate cancer treatment.
Indications and Usage Buserelin may be used in the treatment of hormone-responsive cancers such as prostate cancer or breast cancer, estrogen-dependent conditions (such as endometriosis or uterine fibroids), and in assisted reproduction.
Marketing Status approved; investigational
ATC Code L02AE01
DrugBank ID DB06719
KEGG ID D01831
MeSH ID D002064
PubChem ID 50224
TTD Drug ID D04GSY
NDC Product Code 71052-358
UNII 13U86G7YSP
Synonyms Buserelin | Buserelin Acetate | Acetate, Buserelin | Suprefact | Profact | Receptal | Tiloryth | Suprecur | Bigonist | HOE-766 | HOE 766 | HOE766
Chemical Information
Molecular Formula C62H90N16O15
CAS Registry Number 68630-75-1
SMILES CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=C C=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC( =O)N6.CC(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hostility19.05.01.003--Not Available
Hydronephrosis20.01.05.001--Not Available
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hypersensitivity10.01.03.003--
Immune system disorder10.02.01.001--Not Available
Increased appetite14.03.01.003; 08.01.09.027--Not Available
Infection11.01.08.002--Not Available
Injection site reaction12.07.03.015; 08.02.03.014--
Insomnia19.02.01.002; 17.15.03.002--
Instillation site pain12.07.01.008; 08.02.01.008--Not Available
Leukopenia01.02.02.001--Not Available
Libido decreased21.03.02.005; 19.08.03.001--
Local reaction08.01.03.012--Not Available
Loss of consciousness17.02.04.004--Not Available
Loss of libido19.08.03.003--Not Available
Malaise08.01.01.003--
Menopausal symptoms21.02.02.002--Not Available
Menopause26.03.01.001--Not Available
Menstrual disorder21.01.01.004--Not Available
Mental disability26.01.01.001--Not Available
Migraine24.03.05.003; 17.14.02.001--Not Available
Mood swings19.04.03.001--Not Available
Mouth ulceration07.05.06.004--Not Available
Multiple pregnancy18.08.03.001--Not Available
Musculoskeletal pain15.03.04.007--
Myalgia15.05.02.001--
Nasal dryness22.04.03.002--Not Available
Nasopharyngitis22.07.03.002; 11.01.13.002--Not Available
Nausea07.01.07.001--
Neoplasm16.16.02.001--Not Available
The 3th Page    First    Pre   3 4 5 6    Next   Last    Total 6 Pages